different factor, however, was that 50% of the third group received postoperative radiotherapy compared with only 25 % in the two earlier groups. We feel this was significant in improving the five-year survival rate. Finally, surgical treatment was considerably more aggressive in the third group. This was due to a psychological change as well as to more extensive operations and techniques. In the 1952-1961 series 24 patients with metastases either in the pelvis or in the upper abdomen were cured for more than five years.
Nearly 75% of all ovarian cancer is of the papillary serous type, while the relatively favourable mucinous cancers and granulosa cell cancers account for a scant combined 17 % of the total cases. The majority of Stage Ia patients have lesions that are well differentiated, while most clinical Stage III patients have very poorly differentiated cancers. Patients with cancers that are histologically well differentiated are the only ones with metastases who have any chance of survival.
Total hysterectomy and bilateral salpingooophorectomy is the essential treatment for Stages Ia and lb carcinoma of the ovary. The opposite uninvolved ovary is removed with Stage Ia because of a 12-18 % chance of harbouring a microscopic primary focus ofthe same lesion. Prophylactic omentectomy should be carried out in these cases. There is little value in giving postoperative X-ray therapy to Stage Ia or lb patients with well differentiated tumours. However, if the Ia or lb lesion is poorly differentiated, there certainly can be no disagreement with the decision to administer postoperative X-ray treatment. Stage II and Stage III patients should have maximal surgery carried out at the initial laparotomy. If feasible, total hysterectomy and bilateral salpingo-oophorectomy should be attempted along with careful effort to remove any visible metastases, provided these are few and localized. All these natients should receive postoperative X-ray therapy, to the pelvis alone if Stage II, and to the entire abdomen except for one kidney if Stage IIl.
Chemotherapy is given to patients with residual disease after irradiation and surgery or recurrences. We feel we have enough evidence to show that X-ray therapy has definite value, palliative and sometimes curative. This evidence of improving five-year cure rates still seems to be lacking in chemotherapy, except in isolated cases; for this reason we usually give X-ray therapy first and chemotherapy last. There is no statistically significant difference between the cure rates of Ia lesions treated by bilateral salpingo-oophorectomy and hysterectomy and Ia lesions treated by unilateral oophorectomy. Of about 200 patients with Ia lesions, 150 were treated by complete removal of the internal genitalia and 50 by unilateral oophorectomy. There was only a slight suggestion that radical surgery gives better results with all lesions except the well differentiated mucinous carcinomas, and we therefore feel that conservative therapy is justifiable in a young and childless woman with a well differentiated mucinous carcinoma limited to one ovary. Kottmeier and Williams et al. from the Mayo Clinic have extended this conservative permissiveness to any well differentiated lesion limited to one ovary. As the other ovary harbours a microscopic focus of cancer in 12-18% of cases, a wedge resection biopsy of the conserved ovary would seem a prudent measure with the idea of further surgery for all patients with a poorly differentiated lesion and for those patients with a well, differentiated lesion but no desire for further children.
Mr C N Hudson (St Bartholomew's Hospital, London ECI) and Dr P P Dendy (Addenbrooke's Hospital, Cambridge)'
Aspects of Treatment of More Advanced Cases of Ovarian Cancer
Chemotherapy is the only factor which has added anything to the gloomy outlook of advanced ovarian cancer. In general, however, the treatment of solid tumours has lagged behind the advances made with blood disorders. Not all the measures which have been developed for the latter are necessarily applicable to the wide spectrum of disease that is cancer of the ovary. For instance, at the present time there is little evidence that the use of combinations of drugs is in any way superior to that of a single agent of known efficacy. With present methods, a worth while remission may be obtained in some 40% of advanced cases and its duration is usually around eighteen months. When there is a large residual tumour cell population, a resistant strain of cells soon develops, particularly with the continuous low dose regime. Only a few patients survive more than two years and almost all die of their disease.
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In the search for improved results from chemotherapy, various factors have been considered. The use of higher doses in intermittent or 'pulsed' fashion is now a recognized feature of nearly all chemotherapy regimes. The monitoring of tumour indicator substances can put the control of such regimes on a scientific basis. It is applicable only to the very few primary malignant ovarian tumours which produce hormones in detectable quantities, and is not available for the vast majority of common epithelial tumours. The occurrence of occasional dramatic and prolonged remissions in apparently hopeless disease has fostered the idea that correct selection of the appropriate agent could increase the incidence of such long remissions. This hope is based on the supposition that such super-sensitivity is drugdependent rather than tumour-dependent.
Widespread Disease
In 1968 Professor Limburg described to this Section his technique for a chemotherapeutic sensitivity test using short-term tissue cultures, showing improved mean survival in a group of patients with advanced disease treated with chemotherapy guided by this test (Limburg & Heckmann 1968 , Limburg 1969 . In order to evaluate this claim, two studies have been set up in this country, the first at Cambridge extending to a variety of tumours, by no means confined to gyntecological cancers (Dendy et al. 1970) . A similar study at St Bartholomew's Hospital has been devoted exclusively to the study of ovarian cancer, and has since become incorporated in a wider collaborative study of the whole disease in the North East Metropolitan Region, under the joint auspices of the Regional Association of Obstetricians and Gynmcologists and the Regional Histopathologists Group (C N H and 0 M Curling).
Results
In order to evaluate this sensitivity test, we have had to disregard all patients in whom other treatment modalities may have influenced the outcome. We have therefore included only patients in whom surgery was considered grossly incomplete, but who nevertheless survived 90 days from operation, and did not have radiotherapy to local residual disease. Between the two studies there are now 94 patients who fulfil these criteria, and this represents only 25% of the successful drug tests. These patients have been treated at a variety of hospitals with individual regimes, and the degree to which the test recommendations were followed varied accordingly. Survival may be compared with that of 64 patients from the past decade at St Bartholomew's Hospital who have been treated in a broadly c, palliative surgery only similar fashion by incomplete surgery followed by conventional chemotherapy using a single alkylating agent (Fig 1) . Curve C in Fig 1 records the survival of an earlier group of 57 patients treated by incomplete surgery only, who survived 90 days from operation. These are not strictly comparable populations as there has been an obvious element of selection in the chemotherapy group; they have not been matched for histology or grade. The survival of the treated groups approximates to that recorded elsewhere (Smith et al. 1972 ).
The earlier reports suggesting an improved mean survival seem rather heavily weighted by the presence of one or two long survivors, and we have accordingly preferred the concept of median survival. Even if accurate drug selection were possible, a marked increase in median survival for the selective chemotherapy group would not be anticipated unless for the majority of patients there is a drug capable of producing a long remission. (Regrettably, in most cases no such drug is available or the therapeutic method is inadequate.) One might expect to see evidence of an improved percentage survival in the early months as evidence of the establishment of more short remissions. In contrast, if the in vitro test did not reflect in vivo behaviour at all, one might expect the median survival to be worse than that of patients treated by uniform use of an alkylating agent of recognized value, as useless drugs could be recommended. In actual fact, the survival curve of the patients treated according to the test follows fairly closely that of a conventional alkylating agent group. There is a minor improvement in the median survival and in the percentage surviving at 12 months, but so far the significance level is low (P>0.05). One of us (PPD) has some At this stage one may question the value of such a test, if uniform selection of an agent such as cyclophosphamide can achieve roughly similar results. Its real importance may lie in the fact that some patients can be spared the toxic and unpleasant side-effects of a powerful cytotoxic agent when it has no real chance of producing a remission. In other words, its value is as a test of resistance rather than of sensitivity. Furthermore, by making serial tests on malignant effusions we have, on occasion, clearly demonstrated the early development of resistance to an agent in use. Sometimes serial studies have enabled treatment to be changed on more than one occasion with the production of a second or even a third remission. It is, however, obvious that the method does study the actual cells which threaten the patient and therefore may have further advantages over other model systems for cancer used in the laboratory at a stage when newer and better drugs, which are more selective against human tumour cells, are developed.
The technique is not yet refined enough to study the use of agents in combination, nor to state that the test has passed beyond the experimental stage. For example, there are still problems with the activation of cyclophosphamide in vitro. It is unlikely that the test will provide a major breakthrough in the treatment of Stage III and IV disease, but it is suggested that it may well increase the number of short-term remissions.
Locally Extensive Disease
The development of a resistant cell population is but one of the factors which limits the efficacy of chemotherapy. Others such as blood supply, cell-cycle dependence and tumour immunity are particularly relevant. Because chemotherapy is dangerous and unpleasant, most clinicians have reserved its use for patients with otherwise hopeless disease. There is, however, good reason to believe that the efficacy of antitumour chemotherapy is likely to be greatest whenever the tumour cell population is at its lowest. For locally extensive disease, the use of intensive chemotherapy as an adjunct to extended surgery is an obvious change from the conventional approach of subtotal surgery followed by radiotherapy. When there are visible metastases, it is surely naive to suppose that surgery alone can effectively encompass and eradicate the disease. In ovarian cancer more extensive surgical procedures can only be justified if they improve the survival of patients subsequently treated by chemotherapy or radiotherapy, and do not add to morbidity or mortality. Table 1 reports a small personal series of an extended surgical procedure applicable to late Stage II or early Stage III disease, combined usually with radical chemotherapy. Tumours which have spread in the pouch of Douglas are almost always disrupted or incompletely removed by the standard technique. This operation is an extraperitoneal dissection of the pelvis, removing the peritoneum as a false capsule both to the tumour and pelvic peritoneal metastases (Hudson 1968 Fig 2) .
Although these patients were selected, they are a group for whom the anticipated salvage by radiotherapy or chemotherapy at 2 years would be unlikely to be better than 30%, and at 18 months most of those alive would show evidence of progressive disease. These figures in themselves are of little significance but, as a pilot study, suggest that the combination of more extensive surgery and chemotherapy is perhaps worth further evaluation.
It is, however, only right to refer to the primary morbidity of this operation. It is obvious that it must involve quite frequent incursions into the neighbouring viscera, and this would constitute an unacceptable mutilation if their integrity could not be restored. In practice, this has not proved difficult and the procedure is free of some of the long-term sequele of Wertheim's hysterectomy (Fig 3) . There have been no urinary fistulk but 2 rectal fistulke occurred, one in the patient classed as an operative death. Otherwise the morbidity has been low.
Additional Therapy
High dose chemotherapy has been used in the majority of these patients. Radiotherapy was only used for some of the endometrioid cancers, the dysgerminoma and those in whom there was doubt about macroscopic clearance. In this type of regime, perhaps, there is greater need for the correct selection of chemotherapeutic agents. Certainly one patient, in whom a confident prediction of resistance to cyclophosphamide was ignored, deteriorated with remarkable rapidity.
In summary, this regime represents a determined attempt to achieve control of relatively advanced disease by using in a radical fashion a combination of two therapeutic weapons. For the future, it is possible that immunotherapy will be added as additional measure, but only for those patients in whom the disease can be brought under temporary control by means such as these.
